Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients

A Multicenter, Randomized, Double-Blinded, Monotherapy-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of the Acarbose and Metformin in Loose-Dose Combination Compared to Metformin Monotherapy in Subjects WithType 2 Diabetic Mellitus (T2DM) That is Inadequately Controlled by Metformin Monotherapy

To demonstrate the efficacy and safety of acarbose and metformin loose-dose combination as compared to metformin monotherapy in the treatment of subjects with T2DM that is inadequately controlled by metformin alone

Inclusion Criteria:

• Males and females, aged 18 to less than 80 years
• Diabetes mellitus type 2, that is insufficently controlled with metformin defined by HbA1c between 7.0 % and 10.0%, inclusive
• Body mass index between 22 and 45 kg/m^2, inclusive
• Women and men of reproductive potential must agree to use adequate contraception when sexually active

Exclusion Criteria:

• Fasting plasma glucose > 14.0 mmol/L
• Severe metabolic diabetic complications